@article{2da2bfdee7eb47c98b02d8bd77644a70,
title = "Universal screening for hepatitis C: A needed approach in patients with haematologic malignancies",
keywords = "haematologic malignancies, hematopoietic cell transplantation, hepatitis c, screening",
author = "G. Angelidakis and Hwang, {J. P.} and D. Dandachi and Economides, {M. P.} and J. Hosry and Granwehr, {B. P.} and Torres, {H. A.}",
note = "Funding Information: Dr. Torres is or has been the principal investigator for research grants from Gilead Sciences, Merck & Co., Inc. and Vertex Pharmaceuticals with all funds paid to MD Anderson Cancer Center. Dr. Torres is or has been a paid scientific advisor for Gilead Sciences, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Dynavax Technologies, Vertex Pharmaceuticals and Genentech; the terms of these arrangements are being managed by MD Anderson Cancer Center in accordance with its conflict-of-interest policies. Dr. Hwang has received research funding from Merck & Co. and Gilead Sciences. The other authors declare no competing financial interests.",
year = "2018",
month = sep,
doi = "10.1111/jvh.12913",
language = "English (US)",
volume = "25",
pages = "1102--1104",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "9",
}